Latest Healthcare News

Syntara Limited has reported encouraging Phase 2a results for amsulostat combined with ruxolitinib in treating myelofibrosis, demonstrating sustained symptom improvement and spleen volume reduction over 52 weeks.

Australian Clinical Labs has reached a $6.2 million settlement with the Australian Information Commissioner to resolve a Federal Court case stemming from a 2022 cyberattack on its newly acquired Medlab Pathology business.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

CurveBeam AI Limited has secured A$6.5 million in new capital to fuel global growth of its HiRise™ weight-bearing CT scanner, deepen its partnership with orthopaedic giant Stryker, and advance a potential strategic deal in China.

CurveBeam AI has secured A$6.5 million through an institutional placement and completed a €10 million vendor financing facility to accelerate sales of its HiRise™ CT scanner. The company is also progressing a strategic partnership in China and advancing surgical robot validation.

HITIQ Ltd has raised $250,000 through a premium-priced placement and secured a $1.4 million RDTI loan facility to support its pivot towards consumer concussion management technology.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.

Uscom Limited’s shares have been suspended from trading on the ASX due to concerns over its financial health, following a critical auditor’s disclaimer. The suspension will remain until the company meets regulatory requirements.

Chimeric Therapeutics reports encouraging early clinical trial outcomes for its CHM CDH17 CAR-T therapy, showing disease control and tumour shrinkage at higher dose levels with a strong safety profile.

EMVision Medical Devices launches a $2 million Share Purchase Plan offering shares at a 16.4% discount, bundled with free options exercisable at $3.40, aiming to bolster clinical and commercial milestones.

Bod Science Limited has reported a notable profit turnaround for FY2025, driven by medicinal cannabis sales growth, while navigating a complex Deed of Company Arrangement and a proposed backdoor listing with Biortica Agrimed Limited.